Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis
Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...
NASDAQ: AZN
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...
AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval...
AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions
According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ:...
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...
AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...
Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...
AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...
LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...
AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute...
Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta
Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...
AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....